Granulocyte death mediated by specific antibodies in intravenous immunoglobulin (IVIG)

Granulocytes are key effector cells of the innate immune system that cause substantial by-stander tissue damage in a broad range of inflammatory disorders. Specific antibodies with the potential to regulate granulocyte survival are present in polyclonal intravenous immunoglobulin (IVIG) preparations and may contribute to the anti-inflammatory effects of high-dose IVIG therapy. Here, we discuss idiosyncratic characteristics of antibodies to FAS and Siglecs contained in IVIG pertaining to granulocyte death regulation and highlight implications for research and clinical practice.